FDA Approves Guardant Health's Shield Blood Test for Colorectal Cancer Screening

Aug 7, 2024, 12:11 PM

The US FDA has approved Guardant Health's Shield blood test as the first blood test for primary screening of colorectal cancer (CRC) in adults aged 45 and above at average risk. This approval marks a significant advancement in non-invasive cancer screening options. Additionally, the utility of Guardant Reveal, another liquid biopsy test by Guardant Health, has been validated in the COSMOS study published in Clinical Cancer Research. The study confirms the test's effectiveness in predicting recurrence in colorectal cancer, particularly in Stage II and higher cases.